Fig. 2From: Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and BelgiumOverall and by product treatment discontinuation (total sample) – patients newly initiated on paliperidone palmitate and risperidone microspheresBack to article page